Combined GLP-1, Oxyntomodulin, and Peptide YY Improves Body Weight and Glycemia in Obesity and Prediabetes/Type 2 Diabetes: A Randomized, Single-Blinded, Placebo-Controlled Study
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Roux-en-Y gastric bypass (RYGB) augments postprandial secretion of glucagon-like peptide 1 (GLP-1), oxyntomodulin (OXM), and peptide YY (PYY). Subcutaneous infusion of these hormones (“GOP”), mimicking postprandial levels, reduces energy intake. Our objective was to study the effects of GOP on glycemia and body weight when given for 4 weeks to patients with diabetes and obesity. RESEARCH DESIGN AND METHODS: In this single-blinded mechanistic study, obese patients with prediabetes/diabetes were randomized to GOP (n = 15) or saline (n = 11) infusion for 4 weeks. We also studied 21 patients who had undergone RYGB and 22 patients who followed a very low-calorie diet (VLCD) as unblinded comparators. Outcomes measured were 1) body weight, 2) fructosamine levels, 3) glucose and insulin during a mixed meal test (MMT), 4) energy expenditure (EE), 5) energy intake (EI), and 6) mean glucose and measures of glucose variability during continuous glucose monitoring. RESULTS: GOP infusion was well tolerated over the 4-week period. There was a greater weight loss (P = 0.025) with GOP (mean change −4.4 [95% CI −5.3, −3.5] kg) versus saline (−2.5 [−4.1, −0.9] kg). GOP led to a greater improvement (P = 0.0026) in fructosamine (−44.1 [−62.7, −25.5] µmol/L) versus saline (−11.7 [−18.9, −4.5] µmol/L). Despite a smaller weight loss compared with RYGB and VLCD, GOP led to superior glucose tolerance after a mixed-meal stimulus and reduced glycemic variability compared with RYGB and VLCD. CONCLUSIONS: GOP infusion improves glycemia and reduces body weight. It achieves superior glucose tolerance and reduced glucose variability compared with RYGB and VLCD. GOP is a viable alternative for the treatment of diabetes with favorable effects on body weight.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 5-Year Outcomes
Schauer, P. R., Bhatt, D. L., Kirwan, J. P., Wolski, K., Aminian, A., Brethauer, S. A., Navaneethan, S. D., Singh, R. P., Pothier, C. E., Nissen, S. E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1600869 · Cited by 2,934 · cited 2×
“Glycemic improvement after RYGB is superior to intensive medical management and is sustained, with diabetes remission rates of 26–29% at 5 years (1).”
BackgroundA Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Gut hormone PYY3-36 physiologically inhibits food intake
Batterham, R. L., Cowley, M. A., Small, C. J., Herzog, H., Cohen, M. A., Dakin, C. L., Wren, A. M., Brynes, A. E., Low, M. J., Ghatei, M. A., et al. (2002) · Nature · doi:10.1038/nature00887 · Cited by 2,351
Self-citationLean, M. E., Leslie, W. S., Barnes, A. C., Brosnahan, N., Thom, G., McCombie, L., Peters, C., Zhyzhneuskaya, S., Al-Mrabeh, A., Hollingsworth, K. G., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)33102-1 · Cited by 2,095 · cited 15×
“GLP-1, OXM, and PYY are released from the L cells of the small intestine and colon, and their postprandial secretion is augmented several-fold after RYGB (4,5).”
BackgroundMethodInfluentialInhibition of Food Intake in Obese Subjects by Peptide YY 3–36
Batterham, R. L., Cohen, M. A., Ellis, S. M., Le Roux, C. W., Withers, D. J., Frost, G. S., Ghatei, M. A., & Bloom, S. R. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030204 · Cited by 1,604 · cited 14×
“GLP-1, OXM, and PYY are released from the L cells of the small intestine and colon, and their postprandial secretion is augmented several-fold after RYGB (4,5).”
BackgroundMethodSelf-citationThe SCOFF questionnaire: Assessment of a new screening tool for eating disorders
Morgan, J. F., Reid, F., & Lacey, J. H. (1999) · BMJ · doi:10.1136/bmj.319.7223.1467 · Cited by 1,416
Roux, C. W. L., Aylwin, S. J. B., Batterham, R. L., Borg, C. M., Coyle, F., Prasad, V., Shurey, S., Ghatei, M. A., Patel, A. G., & Bloom, S. R. (2006) · Annals of Surgery · doi:10.1097/01.sla.0000183349.16877.84 · Cited by 985 · cited 2×
“GLP-1 (7-36) amide, PYY (3-36) amide, and OXM were manufactured to Good Manufacturing Practice standards (AmbioPharm).”
BackgroundMethodSelf-citationSubcutaneous Oxyntomodulin Reduces Body Weight in Overweight and Obese Subjects
Wynne, K., Park, A. J., Small, C. J., Patterson, M., Ellis, S. M., Murphy, K. G., Wren, A. M., Frost, G. S., Meeran, K., Ghatei, M. A., et al. (2005) · Diabetes · doi:10.2337/diabetes.54.8.2390 · Cited by 435 · cited 15×
“GLP-1, OXM, and PYY are released from the L cells of the small intestine and colon, and their postprandial secretion is augmented several-fold after RYGB (4,5).”
BackgroundMethodSelf-citationNauck, M. A., Kemmeries, G., Holst, J. J., & Meier, J. J. (2011) · Diabetes · doi:10.2337/db10-0474 · Cited by 392 · cited 15×
“GLP-1, OXM, and PYY are released from the L cells of the small intestine and colon, and their postprandial secretion is augmented several-fold after RYGB (4,5).”
MethodInfluentialSelf-citationWynne, K., Park, A. J., Small, C. J., Meeran, K., Ghatei, M. A., Frost, G. S., & Bloom, S. R. (2006) · International Journal of Obesity · doi:10.1038/sj.ijo.0803344 · Cited by 363 · cited 15×
“GLP-1, OXM, and PYY are released from the L cells of the small intestine and colon, and their postprandial secretion is augmented several-fold after RYGB (4,5).”
BackgroundMethodSelf-citation
Research works printed but not linked: 14
- Bojsen-Møller, 2014, Early enhancements of hepatic and later of peripheral insulin sensitivity combined with increased postprandial insulin secretion contribute to improved glycemic control after Roux-en-Y gastric bypass, Diabetes, 63, 1725, 10.2337/db13-1307 · DOI · Paper page
- Miras, 2013, Mechanisms underlying weight loss after bariatric surgery, Nat Rev Gastroenterol Hepatol, 10, 575, 10.1038/nrgastro.2013.119 · DOI · Paper page
- Drucker, 2018, The ascending GLP-1 road from clinical safety to reduction of cardiovascular complications, Diabetes, 67, 1710, 10.2337/dbi18-0008 · DOI · Paper page
- Cohen, 2003, Oxyntomodulin suppresses appetite and reduces food intake in humans, J Clin Endocrinol Metab, 88, 4696, 10.1210/jc.2003-030421 · DOI · Paper page
- Neary, 2005, Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food intake additively, Endocrinology, 146, 5120, 10.1210/en.2005-0237 · DOI · Paper page
- Schmidt, 2014, Effects of PYY3-36 and GLP-1 on energy intake, energy expenditure, and appetite in overweight men, Am J Physiol Endocrinol Metab, 306, E1248, 10.1152/ajpendo.00569.2013 · DOI · Paper page
- Field, 2010, PYY3-36 and oxyntomodulin can be additive in their effect on food intake in overweight and obese humans, Diabetes, 59, 1635, 10.2337/db09-1859 · DOI · Paper page
- van Strien, 1986, The Dutch Eating Behavior Questionnaire (DEBQ) for assessment of restrained, emotional, and external eating behavior, Int J Eat Disord, 5, 295, 10.1002/1098-108X(198602)5:2<295::AID-EAT2260050209>3.0.CO;2-T · doi:10.1002/1098-108x(198602)5:2<295::aid-eat2260050209>3.0.co;2-t
- Hill, 2013, Expansion of the homeostasis model assessment of β-cell function and insulin resistance to enable clinical trial outcome modeling through the interactive adjustment of physiology and treatment effects: iHOMA2, Diabetes Care, 36, 2324, 10.2337/dc12-0607 · DOI
- Blundell, 2017, Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity, Diabetes Obes Metab, 19, 1242, 10.1111/dom.12932 · DOI · Paper page
- Schmidt, 2016, Effects of RYGB on energy expenditure, appetite and glycaemic control: a randomized controlled clinical trial, Int J Obes, 40, 281, 10.1038/ijo.2015.162 · DOI
- Tharakan, 2017, Roles of increased glycaemic variability, GLP-1 and glucagon in hypoglycaemia after Roux-en-Y gastric bypass, Eur J Endocrinol, 177, 455, 10.1530/EJE-17-0446 · DOI · Paper page
- Hare, 2009, Preserved inhibitory potency of GLP-1 on glucagon secretion in type 2 diabetes mellitus, J Clin Endocrinol Metab, 94, 4679, 10.1210/jc.2009-0921 · DOI · Paper page
- Salinari, 2017, Downregulation of insulin sensitivity after oral glucose administration: evidence for the anti-incretin effect, Diabetes, 66, 2756, 10.2337/db17-0234 · DOI
Cited by
Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand?
Tak, Y. J., & Lee, S. Y. (2021) · Current Obesity Reports · doi:10.1007/s13679-020-00422-w · Cited by 343
Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease.
Baggio, L. L., & Drucker, D. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101090 · Cited by 299
Stefanakis, K., Kokkorakis, M., & Mantzoros, C. S. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156057 · Cited by 142
Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity
Jepsen, M. M., & Christensen, M. B. (2021) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2021.1947240 · Cited by 96
Borland, E., Edgar, C., Stomrud, E., Cullen, N., Hansson, O., & Palmqvist, S. (2022) · Neurology · doi:10.1212/wnl.0000000000200817 · Cited by 83
Metadata
- Authors
- Behary, P., Tharakan, G., Alexiadou, K., Johnson, N., Wewer Albrechtsen, N. J., Kenkre, J., Cuenco, J., Hope, D., Anyiam, O., Choudhury, S., Alessimii, H., Poddar, A., Minnion, J., Doyle, C., Frost, G., Le Roux, C., Purkayastha, S., Moorthy, K., Dhillo, W., Holst, J. J., Ahmed, A. R., Prevost, A. T., Bloom, S. R., & Tan, T. M.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2019-06-08
- Volume
- 42
- Issue
- 8
- Pages
- 1446-1453
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2948323429
- Cited by
- 110
- References
- 15
- FWCI
- 11.36
- Type
- journal article
- Language
- en
- Open access
- green
- Funders
- Medical Research Council (MRC) Experimental Challenge Grant (MR/K02115X/1)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Combined GLP-1, Oxyntomodulin, and Peptide YY Improves Body Weight and Glycemia in Obesity and Prediabetes/Type 2 Diabetes: A Randomized, Single-Blinded, Placebo-Controlled Study. https://app.cochat.ai/papers/10.2337/dc19-0449
- The paper
- Behary, P., Tharakan, G., Alexiadou, K., Johnson, N., Wewer Albrechtsen, N. J., Kenkre, J., Cuenco, J., Hope, D., Anyiam, O., Choudhury, S., Alessimii, H., Poddar, A., Minnion, J., Doyle, C., Frost, G., Le Roux, C., Purkayastha, S., Moorthy, K., Dhillo, W., . . . Tan, T. M. (2019). Combined GLP-1, Oxyntomodulin, and Peptide YY Improves Body Weight and Glycemia in Obesity and Prediabetes/Type 2 Diabetes: A Randomized, Single-Blinded, Placebo-Controlled Study. Diabetes Care. https://doi.org/10.2337/dc19-0449
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.